度普利尤单抗治疗中重度哮喘的长期安全性和有效性(TRAVERSE):一项开放标签扩展研究
TRAVERSE是一项在27个国家362个中心开展的开放标签扩展研究,纳入2282例完成既往度普利尤单抗哮喘研究的中重度或口服糖皮质激素依赖的严重哮喘患者,评估度普利尤单抗300 mg每2周一次最长96周的安全性。
核心结论
- 度普利尤单抗在成人和青少年中重度哮喘患者中延长治疗至148周时安全性和有效性持续。
- 这些发现支持度普利尤单抗在该患者群体中的长期使用。
研究设计与样本
- TRAVERSE为开放标签扩展研究,在27个国家362家医院和临床中心开展。
- 纳入2282例完成既往度普利尤单抗哮喘研究(EXPEDITION、DRI、QUEST或VENTURE)的12-84岁中重度或口服糖皮质激素依赖的严重哮喘患者。
- 度普利尤单抗300 mg每2周一次,最长96周。
- 主要终点为出现任何治疗相关不良事件的患者数量和百分比;次要终点包括年化急性发作率、支气管舒张前FEV1变化、ACQ-5、AQLQ、2型生物标志物和抗药抗体。
- 统计分析为描述性;安全性分析纳入所有入组患者,有效性分析纳入非口服糖皮质激素依赖患者及亚组。
主要发现
- 母研究中接受安慰剂后换用度普利尤单抗的患者支气管舒张前FEV1快速改善,所有结局指标持续改善;继续度普利尤单抗的患者年化急性发作率、哮喘控制和生活质量进一步改善;血嗜酸性粒细胞和血清总IgE逐步下降;抗药抗体状态对安全性或有效性无影响。
临床怎么用
- 度普利尤单抗300 mg每2周一次长期治疗中重度哮喘安全性和有效性持续,支持长期使用。
- 治疗期间需监测常见不良事件如鼻咽炎、注射部位红斑和支气管炎。
- 非口服糖皮质激素依赖患者长期治疗可维持低急性发作率和肺功能改善。
局限性
- 本研究为开放标签扩展研究,统计分析为描述性。
- 有效性分析主要限于非口服糖皮质激素依赖患者及亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as data for extended treatment with dupilumab beyond 1 year are not available. METHODS: TRAVERSE was an open-label extension study in 362 hospitals and clinical centres across 27 countries that assessed the safety and efficacy of dupilumab 300 mg every 2 weeks up to 96 weeks in adults and adolescents (aged 12-84 years) with moderate-to-severe or oral-corticosteroid-dependent severe asthma who had completed a previous dupilumab asthma study (phase 2A EXPEDITION, phase 2B DRI [P2b], phase 3 QUEST, or VENTURE). The primary endpoint was the number and percentage of patients with any treatment-emergent adverse events. Secondary endpoints included annualised exacerbation rate (AER) over the treatment period and change from parent study baseline in pre-bronchodilator FEV1, the five-item asthma control questionnaire (ACQ-5), the asthma quality of life questionnaire (AQLQ), type 2 biomarkers (blood eosinophils and serum total IgE), and anti-drug antibodies (ADAs). Statistical analyses were descriptive. We report safety in all enrolled patients, and efficacy in patients with non-oral-corticosteroid-dependent asthma and in subgroups, including patients with a type 2 inflammatory phenotype who received 148 weeks of treatment. This study is registered with ClinicalTrials.gov, NCT02134028. FINDINGS: Between Aug 5, 2014, and Oct 11, 2019, of 2302 patients assessed for eligibility, 2282 adults and adolescents were enrolled (median age 50 years, 62·1% female and 37·9% male). Safety during TRAVERSE was consistent with the known dupilumab safety profile. The proportion of patients reporting treatment-emergent adverse events throughout the study duration was similar to that observed in the parent studies and ranged from 76·3% to 94·7%. The most frequently reported treatment-emergent adverse events were nasopharyngitis (17·5-25·9%), injection-site erythema (2·2-23·4%), and bronchitis (9·3-19·0%). Serious asthma exacerbations (0·5-3·6%) and pneumonia (0·7-2·7%) were the most frequently reported serious adverse events. There were four treatment-emergent adverse events leading to death. Efficacy during TRAVERSE was also consistent with the results of parent studies. In patients who were non-oral-corticosteroid-dependent, AER remained low (0·277-0·327) across parent study and treatment groups, pre-bronchodilator FEV1 improvements were sustained to the end of treatment at week 96 (mean changes from parent study baseline ranged from 0·22 L [SD 0·44] to 0·33 L [0·44] across parent study and treatment groups), and improvements in ACQ-5 and AQLQ scores were sustained to the last timepoint assessed at week 48. Rapid improvements were observed in pre-bronchodilator FEV1 and sustained improvements were seen in all outcome measures for patients given dupilumab who previously received placebo in parent studies; further improvements in AER, asthma control, and health-related quality of life were observed in patients who continued receiving dupilumab. Blood eosinophils and serum total IgE decreased progressively. ADA status had no effect on safety or efficacy. In the subgroup of patients with a type 2 inflammatory phenotype followed-up for 148 weeks, AER decreased progressively, and initial lung function improvements were sustained over 148 weeks. INTERPRETATION: Data show that safety and efficacy of dupilumab in adult and adolescent patients with moderate-to-severe asthma are sustained when treatment is extended up to 148 weeks. These findings therefore support the long-term use of dupilumab in this patient population. FUNDING: Sanofi and Regeneron Pharmaceuticals.
引用
- Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2021. PMID: 34597534. doi:10.1016/S2213-2600(21)00322-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。